# Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant

Claudio Fozza

*Department of Medical, Surgical and Experimental Sciences, University of Sassari, Viale San Pietro 12, 07100 Sassari, Italy*

A B S T R A C T

Several findings suggest that the pathogenesis and clinical history of myelodysplastic syndromes (MDS) is influenced by a variety of immune pathways and mechanisms. Coherently several therapeutic approaches based on the idea of modulating the immune system have been exploited in this clinical setting. The present review will first consider more consolidated strategies such as antithymocyte globulin and immunomodulatory (IMiDs) analogues. Less explored approaches, such as anti tumor necrosis factor antibodies, cyclosporin and bortezomib will be also evaluated. Finally the potential impact of anti-tumour vaccination or hemopoietic cell transplantation on the outcome of MDS patients will be addressed.

## 1. Introduction

The pathogenesis of myelodysplastic syndromes (MDS) is mainly driven by specific genetic lesions involving the stem cell compartment (Papaemmanuil et al., 2013). However clinical and laboratory findings suggest a potential role for different immune pathways and mechanisms (Fig. 1) (Fozza, 2017). In fact, a variety of autoimmune manifestations impact on the clinical history of around one third of MDS patients (Table 1). These conditions are extremely heterogeneous ranging from localized to systemic disorders and have been reported to potentially involve all sites and organs (Komrokji et al., 2016). Furthermore immunosuppressive treatments, starting with antithymocyte globulin (ATG), have been exploited in a fraction of these patients (Molldrem et al., 1997). Noteworthy, several immune cell subsets are deeply deranged and T-cells have been often advocated for the functional inhibition of hematopoietic precursors. The potential influence on the MDS pathogenesis of a large number of immune cell subsets has been specifically investigated by using different methodological approaches. Historically most studies were focused on cytotoxic T-cells and natural killer cells but more recently new characters, such as for instance regulatory T-cells and mesenchymal stem cells, have been widely evaluated in this clinical context. Relevant findings have been also reported as regards B cells, dendritic cells, macrophages as well as myeloid-derived suppressor cells (Fozza and Longinotti, 2012). The present review will first consider more consolidated strategies such as antithymocyte globulin and immunomodulatory (IMiDs) analogues. Less explored approaches, such as anti Tumor Necrosis Factor antibodies, cyclosporin and bortezomib will be also evaluated. Finally the potential impact of vaccination or stem cell transplantation on the outcome of MDS

patients will be addressed (Table 2).

## 2. Antithymocyte globulin

After the first experiences dating back to 1988 (Tichelli et al., 1988), ten years later 25 transfusion-dependent patients were treated with ATG within a phase II study. Noteworthy, 44% of them responded and became transfusion-independent for a median of 10 months, while 3 of them even showed complete responses (Molldrem et al., 1997). A retrospective multicenter analysis focusing on 96 patients with MDS with a median follow-up of 33.8 months was reported. A total of 40 patients (42%) achieved an hematological response, 30 of which (75%) were durable lasting for a median of 31.5 months. On multivariate analysis, both low International Prognostic Scoring System (IPSS) and bone marrow hypocellularity were independent predictive factors for improved response to ATG while IPSS was the only predictor for overall survival (Lim et al., 2007). In a further prospective study among 61 patients, within 8 months of treatment 34% of them achieved red blood cell transfusion independence which was maintained in 81% of responders for a median of 36 months. Moreover 10 out of 21 patients (47.5%) with severe thrombocytopenia had sustained platelet count increases while 6 out of 11 patients (55%) with severe neutropenia had sustained neutrophil count increases (Molldrem et al., 2002). In a further phase II study 35 patients were treated with either horse or rabbit ATG with no differences in the observed response rates. Shorter disease history and belonging to the refractory anaemia (RA) subgroup correlated with response, whose median duration was 9 months. Noteworthy 23 patients experienced side effects > grade 2, with one patient dying from rhinocerebral mucormicosis (Stadler et al., 2004). In the context

Fig. 1. The immune landscape of myelodysplastic syndromes.

**Table 1**
Most frequent autoimmune manifestations in MDS patients.

| **Haematological** | **Gastrointestinal system** |
| --- | --- |
| autoimmune haemolytic anaemia | Behcet disease |
| immune thrombocytopenia | autoimmune pancreatitis |
| **Vessels** | autoimmune hepatitis |
| large-vessel vasculitis | **Kidneys** |
| Henoch Schönlein purpura | membranous gromerulonephritis |
| leukocytoclastic vasculitis | **Other organs and conditions** |
| **Joints** | systemic lupus erythematosus |
| relapsing polychondritis | Sjogren disease |
| rheumatoid arthritis | hypothyroidism |
| **Skin** | |
| neutrophilic dermatosis | |
| psoriasis | |

**Table 2**
Immune-therapeutic approaches most often exploited in MDS patients.

antithymocyte globulin
thalidomide and its immunomodulatory (IMiDs) analogues
anti tumor necrosis factor antibodies
cyclosporin
bortezomib
sirolimus
temsirolimus
mycophenolate mofetil
alemtuzumab
vaccination strategy
non myeloablative stem cell transplant

of another phase II study T-cell activation profiling was proposed as a possible tool to predict the response to ATG (Komrokji et al., 2014).

After the first studies suggesting a potential role for the combination between ATG and cyclosporin in small cohorts of MDS patients (Yazji et al., 2003; Broliden et al., 2006; Garg et al., 2009), 15 mg/kg of horse ATG for 5 days and oral cyclosporin for 180 days were compared with best supportive care within a phase III trial. Although by month 6, 13 of 45 patients on ATG + cyclosporin had an hematologic response compared with only 4 of 43 patients on best supportive care, no apparent impact on transformation free and overall survival could be demonstrated (Passweg et al., 2011). In the context of a large retrospective study involving 66 patients all of which received ATG and 60% also cyclosporin, this association was shown to offer responses not inferior to other therapies approved for lower risk MDS. High risk revised International Prognostic Scoring System (IPSSR), poor karyotype and treatment after 2 years from diagnosis showed a negative impact on

response rates. The association offered higher response rates than ATG alone while ATG administered in first line or after lenalidomide showed better response trend compared to when administered in third line or after azacytidine (Haider et al., 2016). Factors affecting response and survival in patients treated with ATG and/or cyclosporin were specifically evaluated in 129 patients. Thirty-nine (30%) of them responded either completely or partially: 18 (24%) of 74 patients to ATG only, 20 (48%) of 42 patients to ATG plus cyclosporin, and one (8%) of 13 patients to cyclosporin only. Thirty-one percent (12 of 39) of the responses were complete. In multivariate analysis, younger age was the most significant factor favouring response to therapy while other favourable factors were HLA-DR 15 positivity and combination of ATG plus cyclosporin (Sloand et al., 2008). Most studies evaluating ATG both in monotherapy and in combination confirmed that this drug is not devoid of toxicity, further highlighting the crucial relevance of a well balanced patient selection.

When looking at potential mechanisms of ATG efficacy, responses were associated with a loss of the lymphocyte-mediated inhibition of hematopoietic precursors. In fact in responders peripheral blood lymphocytes suppressed colony forming unit-granulocyte macrophage (CFU-GM) in an ATG reversible way. Moreover, depleting either CD3 + or CD8 + lymphocytes in the bone marrow increased CFU-GM only in responding patients, who also showed a shift of the T-cell receptor (TCR) beta variable (BV) profile from clonal to polyclonal. These findings suggested that cytotoxic T-cell clones mediate the suppression of CFU-GM and, after ATG treatment, are replaced by polyclonal non autoreactive T-cells (Molldrem et al., 1998). Another study examining by spectratyping the TCR repertoires of 12 MDS patients during ATG treatment demonstrated that patients recovering an effective hematopoiesis lost their skewed peaks, thus suggesting loss or reduction of overrepresented clonal T-cell populations. In contrast, patients who did not recover effective hematopoiesis showed persistently skewed repertoires 3 to 6 months after treatment (Kochenderfer et al., 2002). A significant association was shown between HLA DR15 expression and response to immunosuppression as well as occurrence of paroxysmal nocturnal hemoglobinuria. Very likely the DR15 typing could identify a subset of MDS paralleling the immune pathogenesis of aplastic anaemia and susceptible to immunosuppressive treatments. Such an association was potentially explained with either the efficient presentation of bone marrow stem cell-derived antigens by specific HLA molecules or by the correlation with cytokine profiles favouring a pro-inflammatory bone marrow microenvironment (Saunthararajah et al., 2002). It is worth reporting two different possible nuances of the ATG activity which, although deriving from in vitro studies applied to different contexts, fit quite well with the efficacy demonstrated in MDS. In fact ATG has been shown to induce the expansion of CD4 + CD25 + Foxp3 + regulatory T cells (Lopez et al., 2006), which are known to be abnormally distributed in MDS (Fozza et al., 2012), as well as to impair the interactions between T cells and antigen presenting cells (Haidinger et al., 2007). All these findings delineate the ideal MDS patient candidate to ATG and/or cyclosporin as younger, pancytopenic, hypoplastic, at lower risk and displaying normal karyotype beside HLA-DR15- positivity.

## 3. Thalidomide and its immunomodulatory (IMiDs) analogues

Thalidomide is known to act through several mechanisms of action including cytokine inhibition, modulation of cell adhesion to bone-marrow stromal cells, cytotoxic and anti-angiogenic effects. In the largest phase-II study evaluating single agent thalidomide in 83 patients with early and advanced MDS, 18% showed hematologic improvement, including 10 transfusion-dependent patients who became transfusion-independent (Raza et al., 2001). Other studies substantially confirmed these results, although the unfavourable safety profile usually limited long-term administration (Zorat et al., 2001; Bouscary et al., 2005). Noteworthy, several different possible combinations have been exploited with variable results, among which those including erythroid

stimulating agents (Kelaidi et al., 2008; Musto et al., 2006), arsenic trioxide (Raza et al., 2004a; Wei et al., 2012), azacytidine (Raza et al., 2008a; Kenealy et al., 2017), cyclosporin (Xiao et al., 2011) or topotecan (Raza et al., 2006).

Lenalidomide, which shares most of the immunological properties of Thalidomide, has initially showed its efficacy in a non selected MDS population (List et al., 2005). Since then a number of different studies have shown a specific efficacy in patients with 5q deletion especially in the low risk (Fenaux et al., 2011; Oliva et al., 2013; Sánchez-García et al., 2014; Giagounidis et al., 2014; Oliva et al., 2015; Schuler et al., 2016) but potentially also in the high risk setting (Adès et al., 2009; Chen et al., 2012). Major toxicity was represented by neutropenia and thrombocytopenia however in the context of an acceptable benefit/risk profile. Lenalidomide is known to induce ubiquitination and degradation of specific substrates, including casein kinase 1A1, a serine/threonine kinase encoded by a gene within the common deleted region for del5q. The degradation of this protein induces apoptosis via p53 activation. The haploinsufficent expression of CK1A1 in 5q- patients sensitizes cells to lenalidomide action, explaining its efficacy in this setting (Kronke et al., 2015). Interestingly lenalidomide has also shown a possible although less pronounced efficacy also in patients not carrying the 5q deletion (Raza et al., 2008b; Sibon et al., 2012; Santini et al., 2016), even if not all the studies confirmed this potential beneficial effect (Park et al., 2017). In particular an international phase III, randomized, placebo-controlled, double-blind study assessed the efficacy and safety of lenalidomide in transfusion-dependent patients with IPSS lower-risk non-del(5q) MDS ineligible for or refractory to erythropoiesis-stimulating agents. Among 239 patients transfusion independence was achieved in 26.9% of patients and its median duration was 30.9 weeks (Santini et al., 2016). Among the different potential combination, the simultaneous or sequential use of lenalidomide and azacytidine has shown the most promising results (Sekeres MA List et al., 2010; Sekeres et al., 2012; Platzbecker et al., 2013; DiNardo et al., 2015; Mittelman et al., 2016; Sekeres et al., 2017) while preliminary data suggest also a possible efficacy for the combination with bortezomib (Attar et al., 2013). However it should be underlined that until now the combination therapy between lenalidomide and azacytidine has not been demonstrated to be superior to azacitidine monotherapy in terms of overall response rate and survival, mainly for greater toxicity requiring more often dose modification and early treatment discontinuation. More recently higher doses of lenalidomide have been tested in patients with relapsed or refractory high risk MDS and acute myeloid leukemia (AML) with discouraging results (Zeidan et al., 2017). A recent meta-analysis has conclusively confirmed an increased overall survival as well as a reduced rate of progression into AML for patients with 5q deletion (Lian et al., 2016). The immunomodulatory activity of lenalidomide in low-risk MDS patients is at least partially related to its effects on T-cell activity, including reduction in T-cell tolerance, increased effector function and establishment of a normal T-cell homeostasis. In fact, although the in vitro inducible T-cell proliferation was reduced in MDS patients for both CD4+ and CD8+ cells, TCR stimulation in the presence of lenalidomide induced significantly greater proliferation in both cell subsets, beside an increased production of Th1-type cytokines which are effectors of anti-tumor immunity. In vivo, a significant improvement in the ratio of naïve-to-memory T-cells was seen in MDS patients with erythropoietic response to lenalidomide, suggesting that lenalidomide increases proliferation and/or thymic output, therefore improving the homeostasis within the T-cell compartment (Mc Daniel et al., 2012).

## 4. Anti tumor necrosis factor antibodies

After the first attempts in 2002 showing quite conflicting results (Maciejewski et al., 2002; Deeg et al., 2002; Rosenfeld and Bedell, 2002), Infliximab, an anti tumor necrosis factor (TNF)-alpha chimeric monoclonal antibody, was tested in 37 patients with low risk disease,

22% of which showed an hematologic response with a good safety profile (Raza et al., 2004b). Very interestingly, also SCIO-469, a p38 a-mitogen-activated protein kinase inhibitor, which is able to suppress the induction of TNF-alpha, vascular endothelial growth factor (VEGF), IL-6, and IL-1b and is usually applied to rheumatologic disorders, has preliminary shown potential activity in restoring hematopoiesis in MDS progenitors (Navas et al., 2006). The administration of the anti-TNF-alpha monoclonal antibody cA2 reduced the proportion of apoptotic and Fas + cells in the CD34+ cell compartment and increased the clonogenic potential of bone marrow mononuclear and CD34+ cells. Moreover in long-term bone marrow cultures the antibody reduced TNF-alpha levels and significantly improved the hematopoiesis-supporting capacity of adherent cells. Finally the proportion of activated peripheral blood and bone marrow T lymphocytes decreased significantly after treatment, therefore suggesting an immunomodulatory effect of cA2 (Boula et al., 2006). All these preliminary findings should be further exploited in the context of clinical studies.

## 5. Cyclosporin

Haematological responses in terms of anaemia improvement and achievement of transfusion independence were also observed in 82% of cytopenic patients with RA treated with cyclosporin A. A complete trilineage recovery was observed in 23% of patients. Noteworthy responses were long-lasting with follow-up ranging from 5 to 30 months and this treatment was overall well tolerated (Jonásova et al., 1998). Interesting results were also reported in a small cohort of patients with erythroid hypoplasia (Shimamoto et al., 2001). In vitro studies demonstrated that, in patients with hypoplastic MDS, the addition of cyclosporin A to patients lymphocytes significantly decreased the number of IFN-gamma-expressing CD4+ cells. This effect was associated with increased colony formation, giving a possible explanation for the beneficial effect of this agent in this subset of patients (Selleri et al., 2002). Among 50 patients treated with a median dose of 4.58 mg/kg, hematological improvement was observed in 30 (60%) of patients all of them with RA while 4 (8%) of the responders achieved partial remission (PR) once again with a good safety profile. Higher response rate (53%) was shown in the erythroid compared to platelet or neutrophil lineage. Responses were associated with good karyotype or DRB1*1501 subtype (Shimamoto et al., 2003). A literature review confirmed that cyclosporin A therapy is useful for MDS patients with any marrow cellularity and that shorter disease duration and higher cyclosporin A dose are positively correlated with response rates (Ogata et al., 2004). The potential efficacy of such an approach was further confirmed in following studies, showing similar results (Dixit et al., 2005; Chen et al., 2007; Ishikawa et al., 2007). The importance of patient selection, in order to increase response rates and avoid treatment-related AML transformation, has been highlighted in a following trial, in which the response rate to ATG followed by cyclosporin A or cyclosporin A alone appeared to be positively correlated with the number of recruitment criteria met, i.e. IPSS ≤ 1 and at least one of the following criteria: expression of the HLA-DR15 allele, bone marrow cellularity of less than 30%, abnormal immune index of bone marrow T-lymphocytes. The overall response rate was 775%, with only 2 of 71 patients experiencing disease progression (Xiao et al., 2012). In a retrospective analysis among 89 low risk MDS patients treated with cyclosporin A and levamisole, 63 (708%) achieved either complete remission or hematological improvement at 4 months, with an estimate 24 month progression free survival (PFS) of 822% (Li et al., 2015).

## 6. Bortezomib

Although the proteasome inhibitor bortezomib is widely used in different onco-haematologic disorders, its mechanisms of action have been only partially clarified. A potential interest for its use in MDS patients relies on the demonstration that its efficacy is dependent on the

autophagy-mediated lysosomal degradation of the TNF receptor associated factor 6 (TRAF-6) (Fang et al., 2012). Two different studies have shown only a modest activity when administered in monotherapy in both a mixed cohort of MDS subjects (Alimena et al., 2011) or specifically in low-risk patients (Daher et al., 2017). Much better results were demonstrated among 43 higher risk patients. Interestingly responses were seen in 12 of the 43 patients (28%), including 1 complete response, 3 marrow complete responses, 5 partial responses and 3 haematological improvements. These responses were observed in 12 (36%) of the 33 previously untreated patients, compared to none in the 12 previously treated patients. Noteworthy responders showed improved overall survival. Main toxicity was haematological, responsible for infection in 6 patients and bleeding in 3. Three patients with grade 1–2 pre-treatment haematological toxicity developed grade 3–4 toxicity while neuropathy was seen in 12% of patients (Natarajan-Amé et al., 2012).

## 7. Other immunomodulatory approaches

Among 19 patients receiving sirolimus orally for a median of 3.7 months, 3 showed either a major or a minor haematological response according to International Working Group criteria (Platzbecker et al., 2005). On the other side temsirolimus at a dose of 25 mg per week was accompanied by considerable toxicity without beneficial effects in elderly MDS patients (Wermke et al., 2016). Interestingly transfusion independence was also achieved in 3 out 9 low risk MDS patients treated with mycophenolate mofetil (Remacha et al., 2010). Also the tumor growth factor (TGF)-beta receptor I kinase (Zhou et al., 2008) as well as IRAK1, an immune-modulating kinase (Rhyasen et al., 2013), were identified as potential therapeutic targets within in vitro studies.

Noteworthy also the programmed death 1 (PD-1) signaling was shown to be potentially involved in MDS pathogenesis and more importantly to resistance mechanisms to hypomethylating agents, thus suggesting its possible therapeutic targeting in order to overcome such a resistance (Yang et al., 2014; Ørskov et al., 2015).

A non randomized pilot phase I/II study with alemtuzumab monotherapy was performed in 32 patients with MDS who were judged likely to respond to immunosuppressive therapy. Seventeen (77%) out of 22 intermediate-1 and 4 (57%) out of 7 intermediate-2 patients responded with a median time to response of 3 months. Four out of 7 responders with cytogenetic abnormalities had normal cytogenetics by 1 year after treatment. Moreover among 9 responding patients evaluable at 12 months 5 (56%) had normal blood counts and 7 (78%) were transfusion independent. Thirteen patients were hospitalized for infections which were always self-limited. Lymphocyte depletion was universal by 24 h after initiation of infusion, and patients remained lymphopenic for up to 2 years after treatment (Sloand et al., 2010).

Interestingly also the IL8-CXCR2 pathway (Schinke et al., 2015) and p38 MAPK and Tie2 kinases (Bachegowda et al., 2016) were advocated as potential targets, thus opening for ARRY614 -a specific inhibitor of the latter- potential therapeutic avenues (Garcia-Manero et al., 2015).

A single study specifically evaluated the potential efficacy of methylprednisolone with or without cyclosporin A in MDS subjects with less than 5% blast in peripheral blood, less than 10% blast in bone marrow and advanced cytopenia. Among 18 eligible patients 6 responded to immunosuppressive therapy, with no apparent impact from cyclsporin A. In

responders, mean hemoglobin levels were significantly increased and the required red cell transfusion dose was significantly reduced. The duration of response ranged from 4 to 59 months with a median of 14 months. Interestingly a significant difference in the survival rate was observed between responders and non responders (Yamada et al., 2003).

## 8. Vaccination strategy

Whereas many more data have been obtained in AML patients, the immunogenicity of Wilms tumor gene product 1 (WT1)-peptide vaccination was evaluated in a cohort of WT1-expressing patients including also 2 refractory with excess of blasts (RAEB). Both treated patients showed a major neutrophil response lasting for 2 and 10 months, detectable within 4 weeks of treatment and continuing until disease progression. In addition, one of them had a platelet response lasting for 3 months. These clinical results were paralleled by a decrease in WT1 m-RNA levels and by an increase of WT1-tetramer T-cells in both peripheral blood and bone marrow of most patients (Keilholz et al., 2009). The biological background of this promising strategy was further clarified by a following study showing that anti-WT1 CD4+ and CD8+ T-cell immune responses can be detected in MDS patients responsive to immunosuppressive therapy. Noteworthy, WT1-specific CD8+ T-cells consisted in oligoclonal lymphocyte expansions and were able to inhibit autologous bone marrow cells in culture (Sloand et al., 2011). More recently one of two patients with high-risk MDS vaccinated with a mixture of peptides derived from the WT1 protein experienced a prolonged decrease in transfusion dependence (Brayer et al., 2015). In a small cohort of MDS patients also high-dose RHAMM-R3 peptide vaccination was shown to induce specific immunological responses and positive clinical effects in terms of reduction of leukemic blasts or improvement of peripheral blood counts (Greiner et al., 2010). Finally PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, recognized on myeloid leukemia cells by cytotoxic T lymphocytes, has been evaluated within a phase I/II trial showing objective clinical responses paralleled by PR1-specific immune response also in some MDS patients (Qazilbash et al., 2017).

## 9. Non myeloablative hemopoietic cell transplant

Even if most of the efficacy of hemopoietic cell transplantation (HCT) is guaranteed by the anti-neoplastic activity exerted by both the conditioning regimen and donor lymphocytes within the so called graft versus leukaemia effect, we may still hypothesize a room for its immune modulatory properties especially in the context of reduced-intensity conditioning (RIC) transplant programs. Although also in MDS myeloablative and non myeloablative HCT approaches have substantially shown comparable results, most studies are based on mixed cohorts including also AML patients (de Witte et al., 2009; Alyea et al., 2006; Martino et al., 2006). More recently, even if based on a small number of subjects, a survival benefit was suggested for young lower-risk MDS patients without significant comorbidities undergoing a RIC transplant (Lee et al., 2011).

Focusing on more homogeneous and larger cohorts, the outcome of RIC allogeneic HCT was retrospectively evaluated in 43 patients with MDS or AML arising from MDS. All patients engrafted with a median neutrophil recovery of 15 days while the 2-year OS, disease-free survival (DFS), relapse and transplant-related mortality were 53%, 51%, 16% and 35%, respectively. Grade II−IV acute graft-versus-host disease (GVHD) occurred in 63% of patients. There was no significant survival difference between sibling and matched unrelated donor (MUD) HCT whereas the relapse rate was higher among sibling donor recipients when compared to MUD (38 versus 7%) (Nakamura et al., 2007). A following study analysed 128 consecutive patients who received RIC-HCT, 40 of which received azacytidine before transplant. With a median follow-up of 60 months, 3-year OS, relapse-free survival (RFS), cumulative incidence of relapse and non relapse mortality were, respectively, 53% versus 53%, 37% versus 42%, 35% versus 36% and 20% versus 23%, for patients receiving azacytidine or not. Multivariate analysis confirmed the absence of statistical differences in outcome between the two groups of patients (Damaj et al., 2014).

Very recently a busulfan-based RIC was compared with a myeloablative conditioning regimen (MAC) within a prospective, multicenter,

open-label, randomized phase III trial from the European Society of Blood and Marrow Transplantation in 129 patients with MDS or secondary AML. Once again no differences could be shown for engraftment, incidence of acute or chronic GVHD, non relapse mortality, relapse rate at 2 years, relapse-free survival and overall survival (Kröger et al., 2017). Notwithstanding the heterogeneous results obtained in MDS patients it is mandatory to keep in mind the HCT is still the only curative approach available for these patients.

## 10. Response of autoimmune manifestations to therapies for MDS

The biological interplay existing between the MDS pathogenesis and the development of autoimmune manifestations is mirrored by studies demonstrating the improvement or resolution of the latter after MDS modifying therapeutic approaches, among which more often 5-azacytidine and HCT.

In the largest available study the efficacy of azacytidine on autoimmune disorders was retrospectively assessed in 22 patients with MDS or chronic myelomonocytic leukaemia (CMML). Responses of autoimmune disorders were observed in 19 patients (86%) and reduction or discontinuation of steroids and/or immunosuppressive therapy was possible in 16 cases (73%). The evolution of MDS/CMML and autoimmune disorders was concordant in 13 cases (59%): both favourable in 11 cases and both unfavourable in 2. Noteworthy all responses of autoimmune disorders to azacytidine were observed by the third cycle, although about one third of responses improved and became complete between 3 and 6 cycles. Furthermore, although less than 50% of the patients received more than 6 cycles, only 3 relapses were observed (Fraison et al., 2016). In a different study in 11 patients treated with azacytidine, responses of their autoimmune disorders were achieved in 9/11 (80%) and 6/11 (55%) patients at 3 and 6 months, respectively (Mekinian et al., 2016). Noteworthy we have previously demonstrated that most of the T-cell abnormalities observed in MDS patients (Fozza et al., 2009) tend to revert during therapy with azacytidine, especially within the CD4+ subset (Fozza et al., 2015).

Also allogeneic HCT has been able to restore autoimmune disorders in some patients with MDS. The condition most often reported in this field was BD, which was resolved after cord blood HCT in 3 patients (Yamato, 2003; Tomonari et al., 2004; Nonami et al., 2007) and after peripheral blood HCT in one patient (Kook et al., 2014). Interestingly also relapsing polychondritis (Tomomatsu et al., 2012), Takayasu arteritis (Kato et al., 2014) and spondyloarthritis (Simonetta et al., 2015) were reported to respond to non myeloablative, cord blood and fully myeloablative HCT, respectively.

When considering a specular point of view, haematologic improvements have been described in some MDS patients receiving immunosuppressive treatments for their autoimmune manifestations. This scenario was assessed systematically in 30 patients with autoimmune disorders associated with MDS, among which most frequent were skin vasculitis and arthritis. Autoimmune manifestations responded to immunosuppressive therapy (primarily prednisone) in 26/27 patients. Quite strikingly, cytopenias improved substantially in 6 patients, including complete normalization of peripheral blood counts in two patients with cytogenetic remission in one. Patients with an haematological response to immunosuppressive therapy had improved survival. The autoimmune syndrome was implicated as a primary cause of death in 8/17 patients who died (Enright et al., 1995).

## 11. Recent systematic studies and conclusions

Although the pathogenesis of MDS is unequivocally driven by a milieu of molecular mechanisms, over the last few years a large number of studies have highlighted the potential role of specific immune pathways in this context (Fozza et al., 2016; Fozza and Longinotti, 2013). Concomitantly different groups have explored the possible effects of immune-modulating therapeutic approaches. After reporting

several anecdotal cases, these findings have been progressively categorized within more systematic data collection or even clinical studies.

An interesting point of view was quite recently offered by a French multicenter retrospective study assessing the efficacy and safety of different biologics such as TNF-α antagonists, tocilizumab, rituximab and anakinra for systemic inflammatory and autoimmune diseases associated with MDS. Interestingly when several lines of treatment were used, data were analyzed before and at the end of each treatment line and were pooled to compare overall responses. Twenty-nine patients were included and the most common associated disorders were arthritis, relapsing polychondritis and vasculitis. During a 3-year median follow-up a total of 114 lines of treatments were used for all patients: steroids alone (22%), disease-modifying antirheumatic drugs (23%), TNF-α antagonists (14%), anakinra (10%), rituximab (10%), tocilizumab (7%) and azacytidine (9%). Considering all 114 lines, overall response was showed in 54% cases and was more frequent with steroids (78%) and rituximab (66%) than disease-modifying antirheumatic drugs (45%) and other biologics (33%). Rituximab offered better response in vasculitis and TNF-α antagonists in arthritis. During follow-up, 20 patients (71%) presented at least one severe infection (Mekinian et al., 2017).

From a different point of view, the clinical outcomes and predictors of response in patients with MDS treated with immunosuppressive therapies were studied in a large multi-center international cohort including 367 patients from 11 centers in the United States and in Europe. A total of 367 patients received immunosuppressive therapies, whose disease risk according to the IPSS was low (23%), int-1 (68%), or either int-2 or high (9%). The 149 (40.6%) patients in which only prednisone was used were excluded from response and survival analysis. Of the other 198 patients, immunosuppressive therapies used from most to least frequently was ATG (46%), cyclosporin (11%), tacrolimus (5%) and others (8%). ATG was combined with cyclosporin in 25% of patients. One hundred and fourteen of these 198 patients had response criteria reported: 13.2% had a complete remission, 5.3% had a partial response and 31.6% achieved hematologic improvement resulting in an overall response rate of 45%. In contrast, 38.6% of patients had stable disease (SD) and 11.4% had progressive disease (PD). Transfusion independence was achieved in 38.3% of patients. For patients who achieved a response to immunosuppressive therapies or transfusion independence a significant increase in overall survival was demonstrated. In univariate analyses, female sex predicted better overall survival whereas higher-risk IPSS and IPSS-R score predicted worse overall survival. In multivariate analyses, only bone marrow blast > 5% remained a statistically significant predictor of overall survival and no predictive factors for response were identified. Importantly and in comparison to prior reports, age, prior transfusion dependence, MDS risk scores, type of immunosuppressive therapies used, presence of a paroxysmal nocturnal hemoglobinuria or large granular lymphocyte clone and HLA DR15 positivity and mutations were not predictive of response (Stahl et al., 2017).

In conclusion, when considering that a good fraction of subjects with MDS is still candidate to therapeutic approaches which are able to modify only marginally the disease history as well as the unequivocal role of immune mechanisms in the pathogenesis of these disorders, we suggest that a strategy based on the idea of retuning the immune system would deserve to be further exploited in this clinical setting.

## Conflicts of interest

Nothing to declare

## References

Adès, L., Boehrer, S., Prebet, T., Beyne-Rauzy, O., Legros, L., Ravoet, C., Dreyfus, F., Stamatoullas, A., Chaury, M.P., Delaunay, J., Laurent, G., Vey, N., Burcheri, S., Mbida, R.M., Hoarau, N., Gardin, C., Fenaux, P., 2009. Efficacy and safety of

lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. Blood 113, 3947–3952.

Alimena, G., Breccia, M., Musto, P., Cilloni, D., D'Auria, F., Latagliata, R., Sanpaolo, G., Gottardi, E., Saglio, G., Mandelli, F., 2011. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. Leuk. Res. 35, 504–507.

Alyea, E.P., Kim, H.T., Ho, V., et al., 2006. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol. Blood Marrow Transplant. 12, 1047–1055.

Attar, E.C., Amrein, P.C., Fraser, J.W., Fathi, A.T., McAfee, S., Wadleigh, M., Deangelo, D.J., Steensma, D.P., Stone, R.M., Foster, J., Neuberg, D., Ballen, K.K., 2013. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk. Res. 37, 1016–1020.

Bachegowda, L., Morrone, K., Winski, S.L., Mantzaris, I., Bartenstein, M., Ramachandra, N., Giricz, O., Sukrithan, V., Nwankwo, G., Shahnaz, S., Bhagat, T., Bhattacharyya, S., Assal, A., Shastri, A., Gordon-Mitchell, S., Pellagatti, A., Boultwood, J., Schinke, C., Yu, Y., Guha, C., Rizzi, J., Garrus, J., Brown, S., Wollenberg, L., Hogeland, G., Wright, D., Munson, M., Rodriguez, M., Gross, S., Chantry, D., Zou, Y., Platanias, L., Burgess, L.E., Pradhan, K., Steidl, U., Verma, A., 2016. Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia. Cancer Res. 76, 4841–4849.

Boula, A., Voulgarelis, M., Giannouli, S., et al., 2006. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin. Cancer Res. 12, 3099–3108.

Bouscary, D., Legros, L., Tulliez, M., Dubois, S., Mahe, B., BeyneRauzy, O., Quarre, M.C., Vassilief, D., Varet, B., Aouba, A., Gardembas, M., Giraudier, S., Guerci, A., Rousselot, P., Gaillard, F., Moreau, A., Rousselet, M.C., Ifrah, N., Fenaux, P., Dreyfus, F., 2005. Groupe Français des Myélodysplasies (GFM). A nonrandomised doseescalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies. Br. J. Haematol. 131, 609–618.

Brayer, J., Lancet, J.E., Powers, J., List, A., Balducci, L., Komrokji, R., Pinilla-Ibarz, J., 2015. WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides. Am. J. Hematol. 90, 602–607.

Broliden, P.A., Dahl, I.M., Hast, R., Johansson, B., Juvonen, E., Kjeldsen, L., Porwit-MacDonald, A., Sjoo, M., Tangen, J.M., Uggla, B., Oberg, G., Hellstrom-Lindberg, E., 2006. Antithymocyte globulin and cyclosporine A as combination therapy for lowrisk non sideroblastic myelodysplastic syndromes. Haematologica. 91 (May (5)), 66770.

Chen, S., Jiang, B., Da, W., Gong, M., Guan, M., 2007. Treatment of myelodysplastic syndrome with cyclosporin A. Int. J. Hematol. 85, 11.

Chen, Y., Kantarjian, H., Estrov, Z., Faderl, S., Ravandi, F., Rey, K., Cortes, J., Borthakur, G., 2012. A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. Clin. Lymphoma Myeloma Leuk. 12, 341–344.

Daher, M., Hidalgo Lopez, J.E., Randhawa, J.K., Jabbar, K.J., Wei, Y., Pemmaraju, N., Borthakur, G., Kadia, T., Konopleva, M., Kantarjian, H.M., Hearn, K., Estrov, Z., Reyes, S., Bueso-Ramos, C.E., Garcia-Manero, G., 2017. An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. Am. J. Hematol. 92, 674–682.

Damaj, G., Mohty, M., Robin, M., et al., 2014. Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et deThérapie Cellulaire. Biol. Blood Marrow Transplant. 20, 1349–1355.

de Witte, T., Brand, R., Van Biezen, A., et al., 2009. Allogeneic stem cell transplantation for patients with refractory anaemia with matched related and unrelated donors: delay of the transplant is associated with inferior survival. Br. J. Haematol. 146, 627–636.

Deeg, H.J., Gotlib, J., Beckham, C., Dugan, K., Holmberg, L., Schubert, M., Appelbaum, F., Greenberg, P., 2002. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia 16, 162–164.

DiNardo, C.D., Daver, N., Jabbour, E., Kadia, T., Borthakur, G., Konopleva, M., Pemmaraju, N., Yang, H., Pierce, S., Wierda, W., Bueso-Ramos, C., Patel, K.P., Cortes, J.E., Ravandi, F., Kantarjian, H.M., Garcia-Manero, G., 2015. Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2 e1220.

Dixit, A., Chatterjee, T., Mishra, P., Choudhary, D.R., Mahapatra, M., Saxena, R., Choudhry, V.P., 2005. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann. Hematol. 84, 565–568.

Enright, H., Jacob, H.S., Vercellotti, G., Howe, R., Belzer, M., Miller, W., 1995. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br. J. Haematol. 91 (2), 403–408.

Fang, J., Rhyasen, G., Bolanos, L., Rasch, C., Varney, M., Wunderlich, M., Goyama, S., Jansen, G., Cloos, J., Rigolino, C., Cortelezzi, A., Mulloy, J.C., Oliva, E.N., Cuzzola, M., Starczynowski, D.T., 2012. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 120, 858–867.

Fenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., Te Boekhorst, P., Sanz, G., Del Cañizo, C., Guerci-Bresler, A., Nilsson, L., Platzbecker, U., Lübbert, M., Quesnel, B., Cazzola, M., Ganser, A., Bowen, D., Schlegelberger, B., Aul, C., Knight, R., Francis, J., Fu, T., Hellström-Lindberg, E., 2011. MDS004 Lenalidomide del-5q Study Group. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low/Intermediate-1risk myelodysplastic syndromes with del-5q. Blood 118, 3765–3776.

Fozza, C., 2017. The burden of autoimmunity in myelodysplastic syndromes. Hematol.

Oncol. 27 (April). https://doi.org/10.1002/hon.2423. [Epub ahead of print] Review.

Fozza, C., Longinotti, M., 2012. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur. J. Haematol. 88 (5), 380–387.

Fozza, C., Longinotti, M., 2013. The role of T-cells in the pathogenesis of myelodysplastic syndromes: passengers and drivers. Leuk. Res. 37, 201–203.

Fozza, C., Contini, S., Galleu, A., Simula, M.P., Virdis, P., Bonfigli, S., Longinotti, M., 2009. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp. Hematol. 37 (8), 947–955.

Fozza, C., Longu, F., Contini, S., Galleu, A., Virdis, P., Bonfigli, S., Murineddu, M., Gabbas, A., Longinotti, M., 2012. Patients with early-stage myelodysplastic syndromes show increased frequency of CD4+CD25+CD127(low) regulatory t cells. Acta Haematol. 128, 178–182.

Fozza, C., Corda, G., Barraqueddu, F., Virdis, P., Contini, S., Galleu, A., Isoni, A., Dore, F., Angelucci, E., Longinotti, M., 2015. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia. Leuk. Res. 39 (9), 957–963.

Fozza, C., Crobu, V., Isoni, M.A., Dore, F., 2016. The immune landscape of myelodysplastic syndromes. Crit. Rev. Oncol. Hematol. 107, 90–99.

Fraison, J.B., Mekinian, A., Grignano, E., et al., 2016. Efficacy of Azacitidine in auto-immune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk. Res. 43, 137.

Garcia-Manero, G., Khoury, H.J., Jabbour, E., Lancet, J., Winski, S.L., Cable, L., Rush, S., Maloney, L., Hogeland, G., Ptaszynski, M., Calvo, M.C., Bohannan, Z., List, A., Kantarjian, H., Komrokji, R., 2015. A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin. Cancer Res. 21, 985–994.

Garg, R., Faderl, S., Garcia-Manero, G., Cortes, J., Koller, C., Huang, X., York, S., Pierce, S., Brandt, M., Beran, M., Borthakur, G., Kantarjian, H., Ravandi, F., 2009. Phase II study of rabbit antithymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23, 1297–1302.

Giagounidis, A., Mufti, G.J., Mittelman, M., Sanz, G., Platzbecker, U., Muus, P., Selleslag, D., Beyne-Rauzy, O., te Boekhorst, P., del Cañizo, C., Guerci-Bresler, A., Nilsson, L., Lübbert, M., Quesnel, B., Ganser, A., Bowen, D., Schlegelberger, B., Göhring, G., Fu, T., Benettaib, B., Hellström-Lindberg, E., Fenaux, P., 2014. Outcomes in RBC transfusion-dependent patients with Low/Intermediate-1 risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS004 study. Eur. J. Haematol. 93, 429–438.

Greiner, J., Schmitt, A., Giannopoulos, K., et al., 2010. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95, 1191–1197.

Haider, M., Al Ali, N., Padron, E., Epling-Burnette, P., Lancet, J., List, A., Komrokji, R., 2016. Immunosuppressive therapy: exploring an underutilized treatment option for myelodysplastic syndrome. Clin. Lymphoma Myeloma Leuk. 16 (Suppl), S44–S48.

Haidinger, M., Geyeregger, R., Poglitsch, M., Weichhart, T., Zeyda, M., Vodenik, B., Stulnig, T.M., Böhmig, G.A., Hörl, W.H., Säemann, M.D., 2007. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation 84, 117–121.

Ishikawa, T., Tohyama, K., Nakao, S., Yoshida, Y., Teramura, M., Motoji, T., Takatoku, M., Kurokawa, M., Mitani, K., Uchiyama, T., Omine, M., 2007. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-) CD59(-) blood cells predicts platelet response. Int. J. Hematol. 86, 150–157.

Jonásova, A., Neuwirtová, R., Cermák, J., et al., 1998. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br. J. Haematol. 100, 304–309.

Kato, H., Onishi, Y., Nakajima, S., et al., 2014. Significant improvement of Takayasu arteritis after cord blood transplantation in a patient with myelodysplastic syndrome. Bone Marrow Transplant. 49 (3), 458–459.

Keilholz, U., Letsch, A., Busse, A., et al., 2009. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113, 6541–6548.

Kelaidi, C., Park, S., Brechignac, S., Mannone, L., Vey, N., Dombret, H., Aljassem, L., Stamatoullas, A., Adès, L., Giraudier, S., de Botton, S., Raynaud, S., Lepelley, P., Picard, F., Leroux, G., Daniel, M.T., Bouscary, D., Dreyfus, F., Fenaux, P., 2008. Groupe Francophone des Myélodysplasies (GFM). Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk. Res. 32, 1049–1053.

Kenealy, M., Patton, N., Filshie, R., Nicol, A., Ho, S.J., Hertzberg, M., Mills, T., Prosser, I., Link, E., Cowan, L., Zannino, D., Seymour, J.F., 2017. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leuk. Lymphoma 58, 298–307.

Kochenderfer, J.N., Kobayashi, S., Wieder, E.D., et al., 2002. Loss of T-lymphocyte clonal dominance in patients with myelodisplastic syndrome responsive to immunosuppression. Blood 100, 3639–3645.

Komrokji, R.S., Mailloux, A.W., Chen, D.T., et al., 2014. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodyslplastic syndromes indentifying a novel model for response prediction. Haematologica 99, 1176–1183.

Komrokji, R.S., Kulasekararaj, A., Al Ali, N.H., et al., 2016. Autoimmune diseases and myelodysplastic syndromes. Am. J. Hematol. 91 (5), E280–3.

Kook, M.H., Yhim, H.Y., Lee, N.R., et al., 2014. Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation. Korean J. Intern. Med. 29 (1), 123–125.

Kröger, N., Iacobelli, S., Franke, G.N., Platzbecker, U., Uddin, R., Hübel, K., Scheid, C.,

Weber, T., Robin, M., Stelljes, M., Afanasyev, B., Heim, D., Deliliers, G.L., Onida, F., Dreger, P., Pini, M., Guidi, S., Volin, L., Günther, A., Bethge, W., Poiré, X., Kobbe, G., van Os, M., Brand, R., de Witte, T., 2017. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized phase III study of the EBMT (RICMAC trial). J. Clin. Oncol. 35, 2157–2164.

Kronke, J., Fink, E.C., Hollenbach, P.W., et al., 2015. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature 523, 183–188.

Lee, S.E., Kim, Y.J., Yahng, S.A., et al., 2011. Survival benefits from reduced-intensity conditioning in allogeneic stem cell transplantation for young lower-risk MDS patients without significant comorbidities. Eur. J. Haematol. 87, 510–520.

Li, X., Shi, J., Wang, M., et al., 2015. Cyclosporine combined with levamisole for lower-risk myelodysplastic syndromes. Acta Haematol. 134, 138–145.

Lian, X.Y., Zhang, Z.H., Deng, Z.Q., He, P.F., Yao, D.M., Xu, Z.J., Wen, X.M., Yang, L., Lin, J., Qian, J., 2016. Efficacy and safety of lenalidomide for treatment of Low/Intermediate-1-Risk myelodysplastic syndromes with or without 5q deletion: a systematic review and meta-analysis. PLoS One 11, e0165948.

Lim, Z.Y., Killick, S., Germing, U., Cavenagh, J., Culligan, D., Bacigalupo, A., Marsh, J., Mufti, G.J., 2007. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia. 21 (July (7)), 143641.

List, A., Kurtin, S., Roe, D.J., et al., 2005. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549–557.

Lopez, M., Clarkson, M.R., Albin, M., Sayegh, M.H., Najafian, N., 2006. A novel mechanism of action for antithymocyte globulin: induction of CD4 + CD25 + Foxp3 + regulatory T cells. J. Am. Soc. Nephrol. 17, 2844–2853.

Maciejewski, J.P., Risitano, A.M., Sloand, E.M., et al., 2002. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br. J. Haematol. 117, 119–126.

Martino, R., Iacobelli, S., Brand, R., et al., 2006. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 108, 836–846.

Mc Daniel, J.M., Zou, J.X., Fulp, W., et al., 2012. Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation. Leukemia 26, 1425–1429.

Mekinian, A., Grignano, E., Braun, T., et al., 2016. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology Oxford (Oxford) 55, 291–300.

Mekinian, A., Dervin, G., Lapidus, N., Kahn, J.E., Terriou, L., Liozon, E., Grignano, E., Piette, J.C., Rauzy, O.B., Grobost, V., Godmer, P., Gillard, J., Rossignol, J., Launay, D., Aouba, A., Cardon, T., Bouillet, L., Broner, J., Vinit, J., Ades, L., Carrat, F., Salvado, C., Toussirot, E., Versini, M., Costedoat-Chalumeau, N., Fraison, J.B., Guilpain, P., Fenaux, P., Fain, O., GFM, SNFMI, CRI and MINHEMON, 2017. Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients. Autoimmun. Rev. 16, 903–910.

Mittelman, M., Filanovsky, K., Ofran, Y., Rosenbaum, H., Raanani, P., Braester, A., Goldschmidt, N., Kirgner, I., Herishanu, Y., Perri, C., Ellis, M., Oster, H.S., 2016. Israel Myelodysplastic Syndrome Working Group (MDSWG). Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol. Ann. Hematol. 95, 1811–1818.

Molldrem, J.J., Caples, M., Mavroudis, D., Plante, M., Young, N.S., Barrett, A.J., 1997. Antithymocyte globulin for patients with myelodysplastic syndrome. Br. J. Haematol. 99, 699–705.

Molldrem, J.J., Jiang, Y.Z., Stetler-Stevenson, M., Mavroudis, D., Hensel, N., Barrett, A.J., 1998. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br. J. Haematol. 102, 1314–1322.

Molldrem, J.J., Leifer, E., Bahceci, E., Sauntharararajah, Y., Rivera, M., Dunbar, C., Liu, J., Nakamura, R., Young, N.S., Barrett, A.J., 2002. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann. Intern. Med. 137 (August (3)), 15663.

Musto, P., Falcone, A., Sanpaolo, G., Bodenizza, C., 2006. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. Leuk. Res. 30, 385–388.

Nakamura, R., Rodriguez, R., Palmer, J., et al., 2007. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine andmelphalan is associated with durable disease control in myelodysplastic syndrome. Bone Marrow Transplant. 40, 843–850.

Natarajan-Amé, S., Park, S., Ades, L., Vey, N., Guerci-Bresler, A., Cahn, J.Y., Etienne, G., Bordessoule, D., Ravoet, C., Legros, L., Cheze, S., Stamatoullas, A., Berger, E., Schmidt, A., Charbonnier, A., Chaury, M.P., Braun, T., Fenaux, P., Dreyfus, F., 2012. Groupe Francophone des Myélodysplasies (GFM). Bortezomib combined with low-dose cytarabine in Intermediate-2 and high risk myelodysplastic syndromes. A phase I/II Study by the GFM. Br. J. Haematol. 158, 232–237.

Navas, T.A., Mohindru, M., Estes, M., et al., 2006. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 10, 4170–4177.

Nonami, A., Takenaka, K., Sumida, C., et al., 2007. Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet's disease by upfront cord blood transplantation. Intern. Med. 46 (20), 1753–1756.

Ørskov, A.D., Treppendahl, M.B., Skovbo, A., Holm, M.S., Friis, L.S., Hokland, M., Grønbæk, K., 2015. Hypomethylation and up-regulation of PD-1 in T cells by azacitidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 6, 9612–9626.

Ogata, M., Ohtsuka, E., Imamura, T., Ikewaki, J., Ogata, Y., Kohno, K., Nakayama, T., Ono, K., Saburi, Y., Kikuchi, H., Nasu, M., 2004. Response to cyclosporine therapy in patients with myelodysplastic syndrome: a clinical study of 12 cases and literature review. Int. J. Hematol. 80, 35–42.

Oliva, E.N., Lauseker, M., Aloe Spiriti, M.A., Poloni, A., Cortelezzi, A., Palumbo, G.A., Balleari, E., Sanpaolo, G., Volpe, A., Ricco, A., Ronco, F., Alati, C., D'Errigo, M.G., Santacaterina, I., Kündgen, A., Germing, U., Latagliata, R., 2015. Early lenalidomide treatment for low and intermediate1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence. Cancer Med. 4, 1789–1797.

Oliva, E.N., Latagliata, R., Laganà, C., Breccia, M., Galimberti, S., Morabito, F., Poloni, A., Balleari, E., Cortelezzi, A., Palumbo, G., Sanpaolo, G., Volpe, A., Specchia, G., Finelli, C., D'Errigo, M.G., Rodà, F., Alati, C., Alimena, G., Nobile, F., Aloe Spiriti, M.A., 2013. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy. Leuk. Lymphoma 54, 2458–2465.

Papaemmanuil, E., Gerstung, M., Malcovati, L., et al., 2013. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122, 3616–3627.

Park, S., Hamel, J.F., Toma, A., Kelaidi, C., Thépot, S., Campelo, M.D., Santini, V., Sekeres, M.A., Balleari, E., Kaivers, J., Sapena, R., Götze, K., Müller-Thomas, C., Beyne-Rauzy, O., Stamatoullas, A., Kotsianidis, I., Komrokji, R., Steensma, D.P., Fensterl, J., Roboz, G.J., Bernal, T., Ramos, F., Calabuig, M., Guerci-Bresler, A., Bordessoule, D., Cony-Makhoul, P., Cheze, S., Wattel, E., Rose, C., Vey, N., Gioia, D., Ferrero, D., Gaidano, G., Cametti, G., Pane, F., Sanna, A., Germing, U., Sanz, G.F., Dreyfus, F., Fenaux, P., 2017. Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents. J. Clin. Oncol. 35, 1591–1597.

Passweg, J.R., Giagounidis, A.A., Simcock, M., et al., 2011. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. J. Clin. Oncol. 29, 303–309.

Platzbecker, U., Haase, M., Herbst, R., Voigtmann, K., Thiede, C.H., Mohr, B., Schleyer, E., Leopold, T., Orth, M., Hänel, M., Ehninger, G., Bornhäuser, M., 2005. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br. J. Haematol. 128, 625–630.

Platzbecker, U., Braulke, F., Kündgen, A., Götze, K., Bug, G., Schönefeldt, C., Shirneshan, K., Röllig, C., Bornhäuser, M., Naumann, R., Neesen, J., Giagounidis, A., Hofmann, W.K., Ehninger, G., Germing, U., Haase, D., Wermke, M., 2013. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia 27, 1403–1407.

Qazilbash, M.H., Wieder, E., Thall, P.F., et al., 2017. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies. Leukemia 31, 697–704.

Raza, A., Meyer, P., Dutt, D., et al., 2001. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98, 958–965.

Raza, A., Buonamici, S., Lisak, L., Tahir, S., Li, D., Imran, M., Chaudary, N.I., Pervaiz, H., Gallegos, J.A., Alvi, M.I., Mumtaz, M., Gezer, S., Venugopal, P., Reddy, P., Galili, N., Candoni, A., Singer, J., Nucifora, G., 2004a. Arsenic trioxide and thalidomide combination produces multilineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pretherapy EVI1 expression. Leuk. Res. 28, 791–803.

Raza, A., Candoni, A., Khan, U., et al., 2004b. Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk. Lymphoma 45, 2099–2104.

Raza, A., Lisak, L., Billmeier, J., Pervaiz, H., Mumtaz, M., Gohar, S., Wahid, K., Galili, N., 2006. Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes. Leuk. Lymphoma 47, 433–440.

Raza, A., Mehdi, M., Mumtaz, M., Ali, F., Lascher, S., Galili, N., 2008a. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer 113, 1596–1604.

Raza, A., Reeves, J.A., Feldman, E.J., Dewald, G.W., Bennett, J.M., Deeg, H.J., Dreisbach, L., Schiffer, C.A., Stone, R.M., Greenberg, P.L., Curtin, P.T., Klimek, V.M., Shammo, J.M., Thomas, D., Knight, R.D., Schmidt, M., Wride, K., Zeldis, J.B., List, A.F., 2008b. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111, 86–93.

Remacha, A.F., Arrizabalaga, B., Bueno, J., Muñoz, J., Bargay, J., Pedro, C., 2010. Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica 95, 339–340.

Rhyasen, G.W., Bolanos, L., Fang, J., et al., 2013. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell 24, 90–104.

Rosenfeld, C., Bedell, C., 2002. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:fc) in patients with low risk myelodysplastic syndrome. Leuk. Res. 26, 721–724.

Sánchez-García, J., Del Cañizo, C., Lorenzo, I., Nomdedeu, B., Luño, E., de Paz, R., Xicoy, B., Valcárcel, D., Brunet, S., Marco-Betes, V., García-Pintos, M., Osorio, S., Tormo, M., Bailén, A., Cerveró, C., Ramos, F., Diez-Campelo, M., Such, E., Arrizabalaga, B., Azaceta, G., Bargay, J., Arilla, M.J., Falantes, J., Serrano-López, J., Sanz, G.F., 2014. Spanish Group on Myelodysplastic Syndromes (GES MD). Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion. Br. J. Haematol. 166, 189–201.

Santini, V., Almeida, A., Giagounidis, A., Gröpper, S., Jonasova, A., Vey, N., Mufti, G.J., Buckstein, R., Mittelman, M., Platzbecker, U., Shpilberg, O., Ram, R., Del Cañizo, C., Gattermann, N., Ozawa, K., Risueño, A., MacBeth, K.J., Zhong, J., Séguy, F.,

Hoenekopp, A., Beach, C.L., Fenaux, P., 2016. Randomized phase III study of lena-lidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J. Clin. Oncol. 34, 2988–2996.

Saunthararajah, Y., Nakamura, R., Nam, J.M., et al., 2002. HLA-DR15 (DR2) is over-represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100, 1570–1574.

Schinke, C., Giricz, O., Li, W., Shastri, A., Gordon, S., Barreyro, L., Bhagat, T., Bhattacharyya, S., Ramachandra, N., Bartenstein, M., Pellagatti, A., Boultwood, J., Wickrema, A., Yu, Y., Will, B., Wei, S., Steidl, U., Verma, A., 2015. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. Blood 125, 3144–3152.

Schuler, E., Giagounidis, A., Haase, D., Shirneshan, K., Büsche, G., Platzbecker, U., Nolte, F., Götze, K., Schlenk, R.F., Ganser, A., Letsch, A., Braulke, F., Lübbert, M., Bug, G., Schafhausen, P., Bacher, U., Gattermann, N., Wulfert, M., Haas, R., Germing, U., 2016. Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del (5q) (LEMON5). Leukemia 30, 1580–1582.

Sekeres, M.A., Tiu, R.V., Komrokji, R., Lancet, J., Advani, A.S., Afable, M., Englehaupt, R., Juersivich, J., Cuthbertson, D., Paleveda, J., Tabarroki, A., Visconte, V., Makishima, H., Jerez, A., Paquette, R., List, A.F., Maciejewski, J.P., 2012. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodys-plastic syndromes. Blood 120, 4945–4951.

Sekeres, M.A., Othus, M., List, A.F., Odenike, O., Stone, R.M., Gore, S.D., Litzow, M.R., Buckstein, R., Fang, M., Roulston, D., Bloomfield, C.D., Moseley, A., Nazha, A., Zhang, Y., Velasco, M.R., Gaur, R., Atallah, E., Attar, E.C., Cook, E.K., Cull, A.H., Rauh, M.J., Appelbaum, F.R., Erba, H.P., 2017. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J. Clin. Oncol [Epub ahead of print].

Sekeres MA List, A.F., Cuthbertson, D., Paquette, R., Ganetzky, R., Latham, D., Paulic, K., Afable, M., Saba, H.I., Loughran Jr, T.P., Maciejewski, J.P., 2010. Phase I combina-tion trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J. Clin. Oncol. 28, 225–238.

Selleri, C., Maciejewski, J.P., Catalano, L., et al., 2002. Effects of cyclosporine on he-matopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro annd in vivo studies. Cancer 95, 1911–1922.

Shimamoto, T., Iguchi, T., Ando, K., Katagiri, T., Tauchi, T., Ito, Y., Yaguchi, M., Miyazawa, K., Kimura, Y., Masuda, M., Mizoguchi, H., Ohyashiki, K., 2001. Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements. Br. J. Haematol. 114, 358–361.

Shimamoto, T., Tohyama, K., Okamoto, T., Uchiyama, T., Mori, H., Tomonaga, M., Asano, Y., Niho, Y., Teramura, M., Mizoguchi, H., Omine, M., Ohyashiki, K., 2003. Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leuk. Res. 27, 783–788.

Sibon, D., Cannas, G., Baracco, F., Prebet, T., Vey, N., Banos, A., Besson, C., Corm, S., Blanc, M., Slama, B., Perrier, H., Fenaux, P., Wattel, E.:, 2012. Groupe Francophone des Myélodysplasies. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. Br. J. Haematol. 156, 619–625.

Simonetta, F., Guerne, P.A., Tirefort, Y., Masouridi-Levrat, S., Roosnek, E., Chalandon, Y., 2015. Complete and sustained remission of spondyloarthritis after allogeneic hema-topoietic stem cell transplantation for myelodysplastic syndrome. Joint Bone Spine 82 (3), 216–217.

Sloand, E.M., Wu, C.O., Greenberg, P., Young, N., Barrett, J., 2008. Factors affecting response and survival in patients with myelodysplasia treated with im-munosuppressive therapy. J. Clin. Oncol. 26, 2505–2511.

Sloand, E.M., Olnes, M.J., Shenoy, A., Weinstein, B., Boss, C., Loeliger, K., Wu, C.O., More, K., Barrett, A.J., Scheinberg, P., Young, N.S., 2010. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J. Clin. Oncol. 28, 5166–5173.

Sloand, E.M., Melenhorst, J.J., Tucker, Z.C., et al., 2011. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 117, 2691–2699.

Stadler, M., Germing, U., Kliche, K.O., et al., 2004. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodisplastic syndromes. Leukemia 18, 460–465.

Stahl, M., Deveaux, M., de Witte, T.M., Neukirchen, J., Sekeres, M.A., Brunner, A.M., Roboz, G.J., Steensma, D.P., Bhatt, V.R., Platzbecker, U., Cluzeau, T., Prata, P.H., Fenaux, P., Fathi, A.T., Smith, A., Germing, U., Ritchie, E.K., Verma, V., Podoltsev, N.A., Arenillas, L., Prebet, T., Santini, V., Gore, S.D., Komrokji, R.S., Zeidan, A.M., 2017. The use of immunosuppressive therapy (IST) in patients with the myelodys-plastic syndromes (MDS): clinical outcomes and their predictors in a large interna-tional patient cohort. Blood 130 (Suppl (1)), 422.

Tichelli, A., Gratwohl, A., Wuersch, A., Nissen, C., Speck, B., 1988. Antilymphocyte globulin for myelodysplastic syndrome. Br. J. Haematol. 68, 139–140.

Tomomatsu, J., Hamano, Y., Ando, J., Komatsu, N., Sugimoto, K., 2012. Non-myeloa-blative allogeneic BMT for myelodysplastic syndrome successfully controlled accom-panying relapsing polychondritis. Bone Marrow Transplant. 47 (5), 742–743.

Tomonari, A., Tojo, A., Takahashi, T., et al., 2004. Resolution of Behçet's disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syn-drome. Ann. Hematol. 83 (7), 464–466.

Wei, W., Zhou, F., Zhang, Y., Guo, L., Shi, H., Hou, J., 2012. A combination of thalido-mide and arsenic trioxide is effective and well tolerated in patients with myelodys-plastic syndromes. Leuk. Res. 36, 715–719.

Wermke, M., Schuster, C., Nolte, F., Al-Ali, H.K., Kiewe, P., Schönefeldt, C., Jakob, C., von Bonin, M., Hentschel, L., Klut, I.M., Ehninger, G., Bornhäuser, M., Baretton, G., Germing, U., Herbst, R., Haase, D., Hofmann, W.K., Platzbecker, U., 2016. Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS). Br. J. Haematol. 175, 917–924.

Xiao, Z., Xu, Z., Zhang, Y., Qin, T., Zhang, H., Fang, L., 2011. Cyclosporin A and thali-domide in patients with myelodysplastic syndromes: results of a pilot study. Leuk. Res. 35, 61–65.

Xiao, L., Qi, Z., Qiusheng, C., et al., 2012. The use of selective immunosoppressive therapy on myelodisplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression. Am. J. Hematol. 87, 26–31.

Yamada, T., Tsurumi, H., Kasahara, S., Hara, T., Sawada, M., Moriwaki, H., 2003. Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methyl-prednisolone pulse therapy with or without cyclosporin A. J. Cancer Res. Clin. Oncol. 129, 485–491.

Yamato, K., 2003. Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behçet disease. Int. J. Hematol. 77 (1), 82–85.

Yang, H., Bueso-Ramos, C., DiNardo, C., et al., 2014. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypo-methylating agents. Leukemia 28, 1280–1288.

Yazji, S., Giles, F.J., Tsimberidou, A.M., Estey, E.H., Kantarjian, H.M., O'Brien, S.A., Kurzrock, R., 2003. Antithymocyte globulin (ATG)based therapy in patients with myelodysplastic syndromes. Leukemia 17, 2101–2106.

Zeidan, A.M., Smith, B.D., Carraway, H.E., Gojo, I., DeZern, A., Gore, S.D., 2017. A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia. Br. J. Haematol. 176, 241–247.

Zhou, L., Nguyen, A.N., Sohal, D., et al., 2008. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 112, 3434–3443.

Zorat, F., Shetty, V., Dutt, D., Lisak, L., Nascimben, F., Allampallam, K., Dar, S., York, A., Gezer, S., Venugopal, P., Raza, A., 2001. The clinical and biological effects of thali-domide in patients with myelodysplastic syndromes. Br. J. Haematol. 115, 881–894.